Table 4. Association between polymorphisms in the genes of TS, ERCC1, XPD, XPA, XRCC1, GSTP1, GSTT1, and GSTM1 and survival and progression after 5-FU/oxaliplatin chemotherapy.
|
Survival |
Progressiona |
||||
|---|---|---|---|---|---|
| Factors | No. of patients | Relative risk of dyingb and 95% CI | P-valuec | Relative risk of progressiona and 95% CI | P-valuec |
| XPD-751 | 0.049 | 0.76 | |||
| Lys/Lys | 40 | 1 | 1 | ||
| Lys/Gln | 53 | 1.87 (1.06, 3.31) | 1.13 (0.72, 1.78) | ||
| Gln/Gln | 13 | 2.44 (1.09, 5.44) | 1.25 (0.59, 2.67) | ||
| XPD-156 | 0.88 | 0.64 | |||
| A/A | 14 | 1 | 1 | ||
| C/A | 59 | 1.22 (0.55, 2.75) | 0.81 (0.44, 1.49) | ||
| C/C | 30 | 1.18 (0.49, 2.82) | 0.73 (0.36, 1.48) | ||
| Unknown | 3 | ||||
| XPA-5′ | 0.76 | 0.61 | |||
| G/G | 24 | 1 | 1 | ||
| A/G | 53 | 0.88 (0.47, 1.62) | 1.24 (0.70, 2.18) | ||
| A/A | 16 | 1.13 (0.49, 2.45) | 1.37 (0.66, 2.84) | ||
| Unknown | 13 | ||||
| ERCC1-118 | 0.021 | 0.51 | |||
| C/C | 30 | 1 | 1 | ||
| C/T | 45 | 2.29 (1.19, 4.41) | 1.24 (0.73, 2.11) | ||
| T/T | 31 | 1.86 (0.91, 3.83) | 1.36 (0.76, 2.41) | ||
| XRCC1-399 | 0.50 | 0.97 | |||
| Arg/Arg | 44 | 1 | 1 | ||
| Gln/Arg | 51 | 1.07 (0.63, 1.80) | 0.95 (0.60, 1.51) | ||
| Gln/Gln | 10 | 1.58 (0.71, 3.55) | 0.99 (0.47, 2.09) | ||
| Unknown | 1 | ||||
| TS-3′UTR | 0.72 | 0.22 | |||
| +6BP/+6BP | 37 | 1 | 1 | ||
| +6BP/−6BP | 52 | 1.23 (0.70, 2.15) | 1.49 (0.92, 2.40) | ||
| -6BP/−6BP | 13 | 1.18 (0.52, 2.66) | 1.39 (0.70, 2.75) | ||
| Unknown | 4 | ||||
| TS-5′UTR | 0.42 | 0.44 | |||
| 3R/3R | 43 | 1 | 1 | ||
| 2R/3R | 46 | 0.82 (0.49, 1.39) | 0.78 (0.48, 1.26) | ||
| 2R/2R | 16 | 1.32 (0.64, 2.75) | 1.06 (0.55, 2.02) | ||
| 2/4 | 1 | ||||
| GSTP1-105 | 0.019 | 0.011 | |||
| Val/Val | 10 | 1 | 1 | ||
| Ile/Val | 47 | 1.82 (0.71, 4.66) | 1.22 (0.56, 2.67) | ||
| Ile/Ile | 49 | 2.96 (1.15, 7.61) | 2.13 (0.95, 4.76) | ||
| GSTT1 | 0.29 | 0.93 | |||
| Positive | 75 | 1 | 1 | ||
| Negative | 27 | 1.33 (0.78, 2.28) | 0.98 (0.60, 1.60) | ||
| Unknown | 4 | ||||
| GSTM1 | 0.59 | 0.58 | |||
| Positive | 54 | 1 | 1 | ||
| Negative | 48 | 1.14 (0.69, 1.88) | 1.13 (0.72, 1.76) | ||
| Unknown | 4 | ||||
5-FU=5-fluorouracil; CI=confidence interval; GSTP=glutathione S-transferase; TS=thymidylate synthase; UTR=untranslated region.
a
Time to progression was calculated from the time that patient started treatment until the patient was taken off study. If the relative risk is greater than 1, the relative risk can be thought as the average increased risk of progression at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
b
If the relative risk is greater than 1, the relative risk can be thought as the average increased risk of dying at any point in time compared to the reference group. The group with the ratio equal to 1 is the reference group.
c
P-value based on log-rank test.